Skip to content

Effect of Ruji formula combined with shuowang moxibustion on postoperative immune function and circulating tumor cells (DNA) in patients with TNBC

Effect of Ruji formula combined with shuowang moxibustion on postoperative immune function and circulating tumor cells (DNA) in patients with TNBC

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2100004774
Enrollment
Unknown
Registered
2021-04-23
Start date
2021-04-23
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer

Interventions

Sponsors

Foshan hospital of traditional Chinese medicine
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Patients who met the diagnostic criteria of triple negative breast cancer; 2. After standardized treatment in accordance with the guidelines and specifications for breast cancer diagnosis and treatment of China Anti Cancer Association (2015 Edition), the patients with triple negative breast cancer in stage 0-III were in a tumor free state; 3. Aged from 18 to 70 years; 4. ECOG score: 0-1; 5. The expected survival time was more than 9 months; 6. Informed consent to participate in this study, signed informed consent, expected good compliance, follow-up.

Exclusion criteria

Exclusion criteria: 1. Patients with other malignant tumors or immune system diseases (such as AIDS, rheumatism, severe infection, etc.); 2. Previously found to be allergic to drugs contained in Ruji formula and shuowang moxibustion ointment; 3. The skin condition is poor, unable to accept the treatment of shuowang moxibustion; 4. Pregnant women 5. Patients with bone marrow, liver, kidney, heart, lung and immune dysfunction; 6. 3 months before the detection of immune function received treatment that may affect immune function; 7. Other clinical trials were conducted at the same time.

Design outcomes

Primary

MeasureTime frame
Relapse-free survival;

Secondary

MeasureTime frame
Overall survival rate;

Countries

China

Contacts

Public ContactTian Huaqin

Foshan hospital of traditional Chinese medicine

13929969262@139.com+86 13929969262

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026